425: Waters Corporation Announces Proposed Business Combination with BD's Augusta SpinCo
Business Combination Communication
Waters Corporation has filed a communication with the SEC regarding its proposed business combination with Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company, outlining the transaction and associated regulatory disclosures.
Summary
- A proposed business combination is underway between Waters Corporation and Augusta SpinCo Corporation, a wholly owned subsidiary of Becton, Dickinson and Company (BD).
- Waters will file a registration statement on Form S-4, which will include a preliminary and definitive proxy statement/prospectus for Waters stockholders.
- Augusta SpinCo will file a registration statement on Form 10, serving as an information statement/prospectus in connection with its spin-off from BD.
- Investors and security holders of Waters and BD are urged to read the proxy statement/prospectus, information statement/prospectus, and any other related documents filed with the SEC when they become available.
- Directors and executive officers of Waters and BD may be considered participants in the solicitation of proxies from Waters stockholders in connection with the proposed transaction.
Sentiment
Score: 6
Explanation: The document is a formal legal filing about a proposed business combination. While the underlying event (a merger/acquisition) is generally viewed positively for strategic growth, the filing itself is heavily weighted with cautionary statements and risks, making the tone neutral to slightly cautious rather than overtly positive.
Positives
- The proposed business combination aims to create a combined company, implying strategic benefits and potential synergies, though specific details are not provided in this filing.
Negatives
- No specific negative outcomes or results are detailed in this communication, which primarily focuses on the procedural aspects and risks of a proposed transaction.
Risks
- One or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived on a timely basis or at all.
- A governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the proposed transaction, or may require conditions, limitations, or restrictions in connection with such approvals.
- The required approval by the stockholders of Waters may not be obtained.
- The proposed transaction may not be completed on the terms or in the time frame expected by Waters, BD, and SpinCo, or at all.
- Unexpected costs, charges, or expenses may result from the proposed transaction.
- Uncertainty exists regarding the expected financial performance of the combined company following completion of the proposed transaction.
- Failure to realize the anticipated benefits of the proposed transaction, including as a result of delay in completing the proposed transaction or integrating the businesses of Waters and SpinCo, on the expected timeframe or at all.
- The ability of the combined company to implement its business strategy may be challenged.
- Difficulties and delays may occur in the combined company achieving revenue and cost synergies.
- Inability of the combined company to retain and hire key personnel.
- The occurrence of any event could give rise to termination of the proposed transaction.
- Stockholder litigation in connection with the proposed transaction or other litigation, settlements, or investigations may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification, and liability.
- Evolving legal, regulatory, and tax regimes could impact the transaction.
- Changes in general economic and/or industry-specific conditions or any volatility resulting from the imposition of and changing policies around tariffs.
- Actions by third parties, including government agencies, could affect the transaction.
- The anticipated tax treatment of the proposed transaction may not be obtained.
- There is a risk of greater than expected difficulty in separating the business of SpinCo from the other businesses of BD.
- Disruption of management time from ongoing business operations due to the pendency of the proposed transaction.
- Other effects of the pendency of the proposed transaction on the relationship of any of the parties to the transaction with their employees, customers, suppliers, or other counterparties.
Future Outlook
The document outlines the expected timing and structure of the proposed business combination, the ability of the parties to complete the transaction, and the anticipated benefits including the amount and timing of synergies and tax consequences. It also mentions the terms and scope of expected financing in connection with the proposed transaction and the aggregate amount of indebtedness of the combined company following the closing, along with the combined company's future plans, objectives, expectations, and intentions.
Management Comments
- The document references LinkedIn posts made by Waters and Udit Batra, CEO and President of Waters, on July 14, 2025, in connection with the proposed business combination. The specific content of these posts is not provided in the filing.
Industry Context
This proposed business combination between Waters Corporation, a leader in analytical instruments and software, and Augusta SpinCo, a subsidiary of medical technology company BD, suggests a strategic realignment or expansion within the life sciences and diagnostics sectors. Such transactions often aim to consolidate market positions, leverage complementary technologies, or achieve greater operational efficiencies in a competitive and evolving industry.
Legal Proceedings
- There is a risk of stockholder litigation in connection with the proposed transaction.
- There is a risk of other litigation, settlements, or investigations affecting the timing or occurrence of the proposed transaction or resulting in significant costs of defense, indemnification, and liability.
Stakeholder Impact
- Shareholders: Waters stockholders will be required to approve the transaction, and both Waters and BD security holders are urged to review relevant SEC filings.
- Employees: There is a risk of inability to retain and hire key personnel, and potential disruption of management time from ongoing business operations due to the transaction's pendency.
- Customers: Relationships with customers may be affected by the pendency of the proposed transaction.
- Suppliers: Relationships with suppliers may be affected by the pendency of the proposed transaction.
Next Steps
- Waters will file a registration statement on Form S-4, including a preliminary and definitive proxy statement/prospectus.
- SpinCo will file a registration statement on Form 10, serving as an information statement/prospectus.
- The definitive proxy statement/prospectus will be mailed to stockholders of Waters.
- Investors and security holders are urged to read the proxy statement/prospectus, information statement/prospectus, and other documents when they become available.
- Information about participants in proxy solicitations and a description of their direct and indirect interests will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of fiscal year for BD's Annual Report on Form 10-K. |
| 2024-11-27 | BD's Annual Report on Form 10-K for the year ended September 30, 2024, was filed with the SEC. |
| 2024-12-19 | BD's proxy statement for its 2025 annual meeting was filed with the SEC. |
| 2024-12-31 | End of fiscal year for Waters' Annual Report on Form 10-K. |
| 2025-02-25 | Waters' Annual Report on Form 10-K for the year ended December 31, 2024, was filed with the SEC. |
| 2025-04-09 | Waters' proxy statement for its 2025 annual meeting was filed with the SEC. |
| 2025-07-14 | Date of LinkedIn posts by Waters and Udit Batra, CEO and President of Waters, regarding the proposed business combination. |
Keywords
Waters Corporation, Augusta SpinCo Corporation, Becton Dickinson and Company, BD, business combination, merger, acquisition, spin-off, SEC filing, Form 425, proxy statement, prospectus, corporate transaction, life sciences, medical technology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.